Background Heart failure (HF) and atrial arrhythmias (AAs) are two clinical conditions that
characterize the daily clinical practice of cardiologists. In this perspective review, we analyze …

Aims Newly introduced drugs for heart failure (HF) have been reported to improve the
prognosis of HF with preserved ejection fraction (HFpEF) in the lower range of left ventricular …

The left atrium (LA) plays a critical role in receiving pulmonary venous return and modulating
left ventricular (LV) filling. With the onset of exercise, LA function contributes to the …

Aims Patients with heart failure with preserved ejection fraction (HFpEF) are characterized
by impaired diastolic function. Left ventricular (LV) strain–volume loops (SVL) represent the …

Background Presence of left ventricular diastolic dysfunction (DD) is key in the pathogenesis
of heart failure with preserved ejection fraction (HFpEF). However, non-invasive assessment …

Background Beta-blockers are first-line clinical drugs for the treatment of chronic heart
failure (CHF). In the guidelines for cardiac rehabilitation, patients with heart failure who do or …

Background Obesity is associated with left atrial (LA) remodeling (ie, dilatation and
dysfunction) which is an independent determinant of future cardiovascular events. We aimed …

Aims The optimal echocardiographic predictors of cardiovascular outcome in heart failure
(HF) with preserved ejection fraction (HFpEF) are unknown. We aimed to identify …

Background Atrial fibrillation (AF) and heart failure (HF) portends a poor outcome. The HF
universal definition has incorporated Heart Failure with mildly reduced Ejection Fraction …

Recently established heart failure therapies, including sodium glucose co‐transporter 2
inhibitors, angiotensin‐neprilysin inhibitors, and cardiac resynchronization therapy, have led …